The NOX and flavoprotein inhibitor diphenyleneiodonium (DPI), and tyrosine kinase inhibitors, Imatinib and Nilotinib, have both been shown to reduce ROS in preclinical models of BCR/ABL driven leukaemia [114,115]. This evidence concerns the gene ABL1 and leukemia.